ARCHIVES

NCI disclosure of walk-out by Data and Safety Monitoring Board of the National Lung Screening Trial may be harmful, improper, experts say.

This article is from The Cancer Letter archive.

Vol. 30 No. 16 | April 16, 2004

Download PDF Visit The Full Archive

Related Articles

FDA Advisors Uphold Broad Mandate To Limit Use Of ESA Products In Cancer Indications.

May 11, 2007

Radiation Oncologists Form New College To Address Identity

April 12, 1991

In Brief: Mauer Resigns St. Jude Director; Breslow Named DRCCA Board Chairman; Senate Considers Line Items

August 20, 1982

Formal Guidelines For Training Grants Developed By NCI

December 7, 1979

Breast Cancer Task Force Hears Update on Research, Abstract Excerpter

September 19, 1980

Neurocognitive Deficits Affect Future Adult Employment

September 30, 2011